Kyung Hoon Hwang MD, PhD, Presenter: Nothing to Disclose

Duck-Joo Choi MD, Abstract Co-Author: Nothing to Disclose

Sang Yoon Lee PhD, Abstract Co-Author: Nothing to Disclose

Wonsick Choe MD, Abstract Co-Author: Nothing to Disclose

It is known that F-18 FDG PET has a low sensitivity in the detection of hepatocellular carcinoma (HCC). We prospectively compared C-11 acetate PET results to those of F-18 FDG PET in patients with HCCs.

We prospectively analysed four patients (M:F=3:1, Age Range:48-64) with histopathologically or clinically confirmed HCCs underwent C-11 acetate PET and F-18 FDG PET. Whole body C-11 acetate PET was performed 10 min after injection of 555 MBq of C-11 acetate. F-18 FDG PET was done within 2 day before or after C-11 acetate PET.

A total of 22 HCC lesions were confirmed histopathologically or clinically. F-18 FDG PET detected only 8 lesions of them whereas C-11 acetate PET detected 12 lesions. Two false positive lesions were found on both PETs, respectively.

Although the number of patients was very small, C-11 acetate PET may be complementary to F-18 FDG PET and useful in imaging of HCC. Further studies including more patients are needed.

C-11 Acetate PET may be complementary to other images, especially, F-18 FDG PET

Hwang, K, Choi, D, Lee, S, Choe, W, Comparison of C-11 Acetate PET and F-18 FDG PET in Patients with Hepatocellular Carcinoma.  Radiological Society of North America 2007 Scientific Assembly and Annual Meeting, November 25 - November 30, 2007 ,Chicago IL. http://archive.rsna.org/2007/5016637.html